Hodgkin Lymphoma Clinical Trial
Official title:
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Verified date | October 2023 |
Source | Seagen Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.
Status | Terminated |
Enrollment | 12 |
Est. completion date | November 6, 2022 |
Est. primary completion date | November 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL - Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression or relapse after discontinuing treatment - Documentation of disease relapse or progression =6 months after the last dose of brentuximab vedotin - Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique - Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 - Must not be pregnant and, if of childbearing or fathering potential, must agree to use 2 effective contraception methods during study and for 6 months following last dose of study drug Exclusion Criteria: - Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity - Existing Grade 2 or higher peripheral neuropathy - Previously refractory to treatment with brentuximab vedotin - History of a cerebral vascular event, unstable angina, or myocardial infarction within 6 months prior to first dose - History of another malignancy within 3 years before first dose of study drug or any evidence of residual disease from previously diagnosed malignancy - Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for or prophylaxis agent against GvHD - Active cerebral/meningeal disease - History of progressive multifocal leukoencephalopathy (PML) - Active uncontrolled Grade 3 (per NCI CTCAE v5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to first dose of study drug - Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment |
Country | Name | City | State |
---|---|---|---|
United States | Pacific Cancer Medical Center | Anaheim | California |
United States | University of Maryland | Baltimore | Maryland |
United States | Medical University of South Carolina/Hollings Cancer Center | Charleston | South Carolina |
United States | Texas Oncology - Fort Worth | Dallas | Texas |
United States | Karmanos Cancer Institute / Wayne State University | Detroit | Michigan |
United States | Northwest Oncology and Hematology/AMITA | Elk Grove Village | Illinois |
United States | Summit Medical Group | Florham Park | New Jersey |
United States | Texas Oncology - Fort Worth 12th Avenue | Fort Worth | Texas |
United States | The Center for Cancer and Blood Disorders: Fortworth | Fort Worth | Texas |
United States | Houston Methodist Cancer Center | Houston | Texas |
United States | MD Anderson Cancer Center / University of Texas | Houston | Texas |
United States | SCL Health Good Samaritan Medical Center Cancer Centers of Colorado | Lafayette | Colorado |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Norton Cancer Institute | Louisville | Kentucky |
United States | Cardinal Bernardin Cancer Center / Loyola University Medical Center | Maywood | Illinois |
United States | Tulane University Hospital and Clinic | New Orleans | Louisiana |
United States | Memorial Cancer Institute | Pembroke Pines | Florida |
United States | Saint Louis University | Saint Louis | Missouri |
United States | Texas Oncology - San Antonio Medical Center | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Seagen Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria | Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on BICR | Up to 18.3 months | |
Primary | Number of Participants With Adverse Events | An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. | Up to 36 months | |
Primary | Number of Participants With Laboratory Abnormalities | Laboratory data was summarized by the worst post-baseline grade, by NCI CTCAE v5.0 or higher for each parameter. | Up to 36 months | |
Secondary | Duration of Response (DOR) Per BICR According to Modified Lugano Response Criteria | Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first. | Up to 17.1 months | |
Secondary | Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria | PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first. | up to 18.3 months | |
Secondary | Overall Survival (OS) | OS is defined as the time from date of enrollment to date of death due to any cause. | Up to 35.8 months | |
Secondary | Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria | CR rate is defined as the percentage of participants with CR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) | Up to 18.3 months | |
Secondary | ORR Per Investigator Assessment According to Modified Lugano Response Criteria | Objective Response Rate (ORR) is defined as the percentage of participants with CR or PR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on investigator assessment | Up to 18.3 months | |
Secondary | DOR Per Investigator Assessment According to Modified Lugano Response Criteria | Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first. | Up to 17.1 months | |
Secondary | Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria | PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first. | Up to 18.3 months | |
Secondary | Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria | CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014). | Up to 18.3 months | |
Secondary | ORR Per BICR According to Lugano Response Criteria | ORR is defined as the percentage of participants with CR or PR, assessed according to Lugano Criteria for Response Assessment (Cheson 2014) | Up to 18.3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Active, not recruiting |
NCT03617666 -
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Recruiting |
NCT02507479 -
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT02191930 -
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
Completed |
NCT01393106 -
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Terminated |
NCT00992030 -
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
|
Phase 3 | |
Terminated |
NCT00722865 -
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
|
Phase 2 | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT03242902 -
To Decrease Fatigue With Light Therapy
|
Phase 3 | |
Active, not recruiting |
NCT05205512 -
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
|
N/A | |
Recruiting |
NCT03681561 -
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03250962 -
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT04510610 -
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
|
Phase 2/Phase 3 | |
Completed |
NCT06295211 -
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
|
||
Active, not recruiting |
NCT02256137 -
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
|
||
Completed |
NCT02432235 -
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
|
Phase 1 |